Skip to main content

Table 2 Univariate Cox analysis of clinical variables and molecular markers for tamoxifen-treated patients (cohort-1)

From: Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers

Variable 0 to 10 years DEFS   0 to 5 years DEFS   5 to 10 years DEFS  
  Hazard ratio (95% CI) P a P b Hazard ratio (95% CI) P a P b Hazard ratio (95% CI) P a P b
Age 1.02 (1.00, 1.04) 0.021 0.657 1.02 (0.99, 1.04) 0.153 0.214 1.04 (1.00, 1.08) 0.042 0.168
Stage T2/3 vs T1 2.71 (1.76, 4.19) <0.0001 0.581 2.51 (1.47, 4.26) 0.0007 0.211 3.14 (1.49, 6.64) 0.003 0.164
Node-positive vs -negative 2.47 (1.75, 3.48) <0.0001 0.964 2.51 (1.65, 3.82) <0.0001 0.732 2.67 (1.44, 4.97) 0.002 0.941
Grade          
   Intermediate vs low 2.19 (1.20, 3.99) 0.011 0.11 3.97 (1.57, 9.99) 0.003 0.175 1.04 (0.44, 2.45) 0.934 0.192
   High vs low 2.96 (1.56, 5.62) 0.0009 5.05 (1.92, 13.3) 0.001 1.66 (0.67, 4.12) 0.277
HER2-positive vs -negative 2.64 (1.43, 4.90) 0.002 0.029 3.68 (1.91, 7.10) 0.0001 0.369 0.72 (0.11, 5.26) 0.75 0.141
High MKS vs low MKS 2.96 (2.07, 4.25) <0.0001 0.04 3.89 (2.42, 6.24) <0.0001 0.473 1.90 (1.04, 3.46) 0.036 0.377
Low ERS vs high ERS 2.00 (1.41, 2.83) <0.0001 0.0008 3.26 (2.04, 5.19) <0.0001 0.091 0.91 (0.50, 1.66) 0.763 0.728
MKS/ERS combined groups          
   LowMKS/lowERS vs lowMKS/highERS 2.37 (1.29, 4.35) 0.005 <0.0001 1.98 (0.87, 4.51) 0.104 0.285 3.36 (1.29, 8.73) 0.013 0.862
   HighMKS/highERS vs lowMKS/highERS 3.66 (2.04, 6.57) <0.0001 2.46 (1.09, 5.54) 0.029 6.59 (2.62, 16.6) <0.0001
   HighMKS/lowERS vs lowMKS/highERS 5.35 (3.12, 9.17) <0.0001 7.78 (3.97, 15.3) <0.0001 1.46 (0.45, 4.79) 0.531
Other genomic signatures          
High GGI vs low GGI 2.73 (1.94, 3.86) <0.0001 0.005 3.81 (2.43, 5.97) <0.0001 0.296 1.64 (0.90, 2.99) 0.109 0.02
Mammaprint poor vs good 2.93 (1.91, 4.49) <0.0001 0.22 3.59 (2.02, 6.30) <0.0001 0.768 2.30 (1.16, 4.56) 0.017 0.184
Three-gene model SCMGENE          
   ER+/HER2-highP vs ER+/HER2-lowP 2.13 (1.47, 3.08) <0.0001 0.017 2.58 (1.59, 4.18) 0.0001 0.585 1.60 (0.87, 2.95) 0.127 0.197
   HER2+ vs ER+/HER2-lowP 4.06 (2.09, 7.86) <0.0001 6.63 (3.17, 13.9) <0.0001 0.89 (0.12, 6.64) 0.909
   ER-/HER2- vs ER+/HER2-lowP 2.55 (1.01, 6.42) 0.048 4.70 (1.79, 12.3) 0.002 NA  
PAM50          
   LumB vs lumA 3.01 (2.01, 4.51) <0.0001 0.004 3.84 (2.21, 6.65) <0.0001 0.109 2.26 (1.20, 4.24) 0.011 0.147
   HER2 vs lumA 8.88 (4.36, 18.1) <0.0001 14.4 (6.37, 32.8) <0.0001 2.37 (0.31, 17.9) 0.403
   Basal vs lumA 3.03 (1.07, 8.58) 0.036   6.48 (2.17, 19.4) 0.0008   NA   
  1. aP-value generated by univariate Cox analysis. bP-value for the test of the proportional hazard assumption based on the scaled Schoenfeld residuals. P-values in boldface were statistically significant at P<0.05. DEFS, distant event-free survival; MKS, mitotic kinase score; ERS, estrogen-related score; GGI, genomic grade index; Lum, luminal; ER+/HER2-lowP, ER-positive/human epidermal growth factor receptor 2 (HER2)-negative low proliferation; ER+/HER2-highP, ER-positive/HER2-negative high proliferation; NA, not applicable.